Investor Call:
OVATION-3, Phase 3 Study Design

March 25, 2025



Safe Harbor Statement

This presentation and any statements made during the presentation contain forward-looking statements related to Imunon, Inc. ("Imunon" or the "Company") under the "safe harbor" provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing for commencement and potential outcome of a Phase 3 trial of IMNN-001, the timing and enrollment of the Company's clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company's products, if approved, the potential efficacy and safety profile of the Company's product candidates, and the Company's plans and expectations with respect to its development programs more generally, are forward-looking statements. Imunon generally identifies forward-looking statements by using words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the ability to obtain additional funds for operations; the need for Imunon to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. Imunon assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

OVATION-3 Pivotal Trial: Finalized Phase 3 Study Design with FDA

Randomized, multicenter Phase 3 trial to evaluate the safety and efficacy of IMNN-001 (100 mg/m²) plus standard of care neoadjuvant and adjuvant chemotherapy (NACT) vs SOC NACT alone



1:1 Randomization

Standard of Care
Neoadjuvant Chemotherapy (NACT)
Interval Debulking Surgery
Adjuvant Chemotherapy

+ / –

IMNN-001

Maintenance: FDA approved PARPi therapy for HRD* participants

Treatment Arms stratified by: Stage (Stage IIIc, IV) & HR Deficiency*

Newly diagnosed, high-grade non-mucinous epithelial ovarian, fallopian tube or peritoneal cancer. ECOG score of 0, 1 or 2. Eligible to receive neoadjuvant chemotherapy

Primary Endpoint: Overall Survival
Secondary Endpoints: Surgical Response Score, Chemotherapy Response Score, Clinical Response (ORR), Time to 2nd line treatment

Innovative Statistical Design

Two event-driven Interim Analyses allowing the possibility for early stopping success and regulatory filing

*HR Deficiency: Homologous Recombinant Deficiency

Designed with Operational Flexibility